MS
MCID: MLT020
MIFTS: 75

Multiple Sclerosis (MS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Multiple Sclerosis

MalaCards integrated aliases for Multiple Sclerosis:

Name: Multiple Sclerosis 57 38 12 76 53 25 54 75 37 55 6 43 44 15 73
Ms 57 53 25 75
Multiple Sclerosis, Disease Progression, Modifier of 57 13
Multiple Sclerosis Modifier of Disease Progression 29 6
Disseminated Sclerosis 57 25
Multiple Sclerosis, Susceptibility to, 1 57
Multiple Sclerosis, Susceptibility to 57
Multiple Sclerosis Susceptibility to 40
Generalized Multiple Sclerosis 12
Multiple Sclerosis 1 57
Insular Sclerosis 12

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
onset 20-55 years of age
women affected more than men (3:2)
association with the hla-drb1*1501-dqb1*0602 haplotype has been repeatedly demonstrated in high-risk (northern european) populations.


HPO:

32
multiple sclerosis:
Inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 57 126200
Disease Ontology 12 DOID:2377
ICD10 33 G35
ICD9CM 35 340
MeSH 44 D009103
NCIt 50 C3243
SNOMED-CT 68 24700007
MedGen 42 C1868685
KEGG 37 H01490
UMLS 73 C0026769

Summaries for Multiple Sclerosis

NINDS : 54 An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.  Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is the nerve-insulating myelin that comes under assault. Such assaults may be linked to an unknown environmental trigger, perhaps a virus. Most people experience their first symptoms of MS between the ages of 20 and 40; the initial symptom of MS is often blurred or double vision, red-green color distortion, or even blindness in one eye.  Most MS patients experience muscle weakness in their extremities and difficulty with coordination and balance.  These symptoms may be severe enough to impair walking or even standing. In the worst cases, MS can produce partial or complete paralysis.  Most people with MS also exhibit paresthesias, transitory abnormal sensory feelings such as numbness, prickling, or "pins and needles" sensations.  Some may also experience pain.  Speech impediments, tremors, and dizziness are other frequent complaints. Occasionally, people with MS have hearing loss. Approximately half of all people with MS experience cognitive impairments such as difficulties with concentration, attention, memory, and poor judgment, but such symptoms are usually mild and are frequently overlooked.  Depression is another common feature of MS.

MalaCards based summary : Multiple Sclerosis, also known as ms, is related to pediatric multiple sclerosis and optic neuritis, and has symptoms including seizures, tremor and back pain. An important gene associated with Multiple Sclerosis is PDCD1 (Programmed Cell Death 1), and among its related pathways/superpathways are MicroRNAs in cancer and Cell adhesion molecules (CAMs). The drugs 4-Aminopyridine and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include Neural Tube and Limb, and related phenotypes are diplopia and emotional lability

Disease Ontology : 12 A demyelinating disease that involves damage to the fatty myelin sheaths around the axons of the brain and spinal cord resulting in demyelination and scarring.

Genetics Home Reference : 25 Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system.

NIH Rare Diseases : 53 Multiple sclerosis (MS) is a degenerative disorder that affects the central nervous system, specifically the brain and the spinal cord. The disorder is characterized by destruction of the myelin, the fatty tissue that surrounds and protects the nerve fibers and promotes the transmission of nerve impulses, and damage to nerve cells. The symptoms vary widely from person to person, and may include sensory disturbances in the limbs, problems with muscle control, tremors, muscle stiffness (spasticity), exaggerated reflexes (hyperreflexia), weakness, difficulty walking, poor bladder control, and vision problems. Most patients have periods during which they have symptoms (clinical attacks). The clinical attacks are typically followed by periods without any symptoms (remission). After several years, the symptoms worsen continuously. Multiple sclerosis is considered an autoimmune disorder but the exact cause is unknown. Risk factors for developing multiple sclerosis include genetic factors like changes in the HLA-DRB1 gene and in the IL7R gene and environmental factors, such as exposure to the Epstein-Barr virus, low levels of vitamin D, and smoking. The goal of treatment of MS is to decrease attacks and the inflammation within the central nervous system.

MedlinePlus : 43 Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body, leading to the symptoms of MS. They can include Visual disturbances Muscle weakness Trouble with coordination and balance Sensations such as numbness, prickling, or "pins and needles" Thinking and memory problems No one knows what causes MS. It may be an autoimmune disease, which happens when your immune system attacks healthy cells in your body by mistake. Multiple sclerosis affects women more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak, or walk. There is no single test for MS. Doctors use a medical history, physical exam, neurological exam, MRI, and other tests to diagnose it. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

UniProtKB/Swiss-Prot : 75 Multiple sclerosis: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

Wikipedia : 76 Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the... more...

Description from OMIM: 126200

Related Diseases for Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1104)
# Related Disease Score Top Affiliating Genes
1 pediatric multiple sclerosis 34.0 HLA-DRB1 HLA-DQB1
2 optic neuritis 32.9 MBP HLA-DRB1 CCR5
3 acute disseminated encephalomyelitis 32.7 MBP HLA-DRB1 HLA-DQB1
4 hypersomnia 32.5 HLA-DRB1 HLA-DQB1
5 autoimmune disease 31.2 PDCD1 MBP HLA-DRB1 HLA-DQB1
6 systemic lupus erythematosus 30.7 TNFRSF1A PDCD1 MIR223 HLA-DRB1 HLA-DQB1 CCR5
7 autoimmune hepatitis 30.6 PDCD1 HLA-DRB1 HLA-DQB1
8 leishmaniasis 30.1 HLA-DRB1 HLA-DQB1 CCR5
9 guillain-barre syndrome 30.0 TNFRSF1A MBP HLA-DQB1
10 autoimmune disease of the nervous system 30.0 MBP HLA-DRB1 CCR5
11 lichen sclerosus 29.9 HLA-DRB1 HLA-DQB1
12 pityriasis rosea 29.9 HLA-DRB1 HLA-DQB1
13 primary biliary cirrhosis 29.9 MIR223 MIR20A MIR326
14 marburg acute multiple sclerosis 12.6
15 relapsing-remitting multiple sclerosis 12.6
16 secondary progressive multiple sclerosis 12.5
17 primary progressive multiple sclerosis 12.5
18 multiple sclerosis 5 12.5
19 multiple sclerosis 3 12.5
20 tumefactive multiple sclerosis 12.5
21 progressive relapsing multiple sclerosis 12.4
22 multiple sclerosis 2 12.3
23 multiple sclerosis 4 12.3
24 disseminated sclerosis with narcolepsy 12.2
25 multiple sclerosis-ichthyosis-factor viii deficiency syndrome 12.1
26 neuromyelitis optica 11.9
27 leukodystrophy, demyelinating, adult-onset, autosomal dominant 11.7
28 autosomal dominant leukodystrophy with autonomic disease 11.6
29 trigeminal neuralgia 11.5
30 allergic encephalomyelitis 11.4
31 spasticity 11.4
32 pars planitis 11.4
33 alexander disease 11.4
34 progressive multifocal leukoencephalopathy 11.3
35 tremor 11.3
36 cerebral atrophy 11.3
37 dysphagia 11.3
38 optic nerve disease 11.3
39 intermediate uveitis 11.3
40 pseudobulbar affect 11.3
41 foot drop 11.3
42 balo concentric sclerosis 11.3
43 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.3
44 patulous eustachian tube 11.3
45 leber hereditary optic neuropathy 11.3
46 retinal vasculitis 11.3
47 nervous system disease 11.3
48 stiff-person syndrome 11.2
49 rickets 11.2
50 locked-in syndrome 11.2

Comorbidity relations with Multiple Sclerosis via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Neurogenic Bladder Paraplegia
Trigeminal Neuralgia

Graphical network of the top 20 diseases related to Multiple Sclerosis:



Diseases related to Multiple Sclerosis

Symptoms & Phenotypes for Multiple Sclerosis

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Eyes:
diplopia
vision loss, monocular

Neurologic Peripheral Nervous System:
incoordination
weakness
paresthesias
sensory loss

Laboratory Abnormalities:
increased csf immunoglobulin levels
oligoclonal bands in csf
myelin basic protein in csf

Neurologic Central Nervous System:
emotional lability
spasticity
depression
high intensity area in white matter on head mri
cognitive dysfunction
more
Genitourinary Bladder:
incomplete bladder emptying
incontinence
hesitancy


Clinical features from OMIM:

126200

Human phenotypes related to Multiple Sclerosis:

32 (show all 10)
# Description HPO Frequency HPO Source Accession
1 diplopia 32 HP:0000651
2 emotional lability 32 HP:0000712
3 depressivity 32 HP:0000716
4 spasticity 32 HP:0001257
5 muscle weakness 32 HP:0001324
6 paresthesia 32 HP:0003401
7 urinary incontinence 32 HP:0000020
8 incoordination 32 HP:0002311
9 urinary hesitancy 32 HP:0000019
10 cns demyelination 32 HP:0007305

UMLS symptoms related to Multiple Sclerosis:


seizures, tremor, back pain, pain, headache, hemiplegia, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, muscle cramp

Drugs & Therapeutics for Multiple Sclerosis

Drugs for Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 654)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2,Phase 1 504-24-5 1727
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
4
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
6
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 189261-10-7
7
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145155-23-3
8
acetic acid Approved Phase 4,Phase 3 64-19-7 176
9
Gabapentin Approved, Investigational Phase 4,Phase 2,Not Applicable 60142-96-3 3446
10
Ethanol Approved Phase 4,Phase 3,Not Applicable 64-17-5 702
11
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2,Not Applicable 56-12-2 119
12
Interferon beta-1a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 145258-61-3 6438354
13
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65271-80-9 4212
14
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 112111-43-0
15
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68693-11-8 4236
16
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 216503-57-0
17
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
18
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
19
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
20
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 19982-08-2 4054
21
Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
22
leucovorin Approved Phase 4,Phase 3,Phase 1,Early Phase 1 58-05-9 6006 143
23
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 59-05-2, 1959-05-2 126941
24
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
25
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925
26
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 174722-31-7 10201696
27
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
28 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
30
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
31
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4291-63-8 20279
32
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
33
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 624-49-7 637568 5271565
34
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
35
Suvorexant Approved, Investigational Phase 4 1030377-33-3
36 Piracetam Approved, Investigational Phase 4 7491-74-9
37
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
38
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
39
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
40
Peppermint oil Approved, Investigational Phase 4,Phase 3 8006-90-4
41
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078
42
Peppermint Approved Phase 4,Phase 3
43
Montelukast Approved Phase 4,Phase 1,Phase 2 158966-92-8 5281040
44
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
45
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
46
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
47
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
48 Mirabegron Approved Phase 4,Phase 2,Phase 3 223673-61-8
49
Tocopherol Approved, Investigational Phase 4,Phase 1,Phase 2 1406-66-2 14986
50
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676

Interventional clinical trials:

(show top 50) (show all 2004)
# Name Status NCT ID Phase Drugs
1 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
2 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
3 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
4 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
5 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
6 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
7 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
8 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
9 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
10 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
11 Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients Unknown status NCT01772875 Phase 4
12 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
13 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
14 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®;Rebif®
15 Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) Recruiting NCT03369665 Phase 4 Mavenclad®
16 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
17 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4 Rebif®
18 Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) Recruiting NCT03073603 Phase 4 Discontinuation of disease modifying therapy;Standard of Care
19 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4 Placebo
20 Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis Recruiting NCT03345940 Phase 4 Fingolimod;Dimethyl Fumarate
21 Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis Completed NCT02461069 Phase 4 Dimethyl fumarate
22 Evaluation of the Onset of Action in Highly Active Multiple Sclerosis (MS) Recruiting NCT03364036 Phase 4 Mavenclad®
23 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
24 Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue Recruiting NCT03621761 Phase 4 Modafinil
25 Pharmacogenetic Study in Patients With Relapsing Forms of Multiple Sclerosis Who Developed ITP After Receiving Lemtrada Recruiting NCT03784898 Phase 4 Alemtuzumab (GZ402673)
26 Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis Withdrawn NCT02472938 Phase 4 dimethyl fumarate
27 Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis Recruiting NCT03135249 Phase 4 Alemtuzumab
28 A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Completed NCT01216072 Phase 4 Fingolimod;Standard MS DMTs
29 Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate Terminated NCT02901106 Phase 4 Dimethyl fumarate
30 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
31 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
32 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
33 A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia Recruiting NCT03110315 Phase 4 Suvorexant;Placebo
34 Towards Personalized Dosing of Natalizumab in Multiple Sclerosis Active, not recruiting NCT03516526 Phase 4 Natalizumab
35 Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide Active, not recruiting NCT01970410 Phase 4 teriflunomide
36 Levetiracetam in Central Pain in Multiple Sclerosis(MS) Completed NCT00423527 Phase 4 levetiracetam
37 A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod Recruiting NCT03257358 Phase 4 Fingolimod
38 pH Imaging in Multiple Sclerosis Recruiting NCT03028675 Phase 4 Gd-DTPA-ST;Control
39 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
40 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
41 Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients. Terminated NCT02343159 Phase 4 dimethyl fumarate
42 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
43 Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse Completed NCT01986998 Phase 4 Methylprednisolone 1250 mg/24h x3 days;Oral Methylprednisolone 625 mg/24h x3 days
44 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Completed NCT00315367 Phase 4 Donepezil HCI (drug)
45 Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. Recruiting NCT02849782 Phase 4 Fampridine
46 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
47 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
48 Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis Completed NCT01480076 Phase 4 Fampridine
49 Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Terminated NCT01701856 Phase 4 Interferon beta-1b
50 The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients Terminated NCT01005095 Phase 4

Search NIH Clinical Center for Multiple Sclerosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Sclerosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Multiple Sclerosis:
Autologous bone marrow-derived hematopoietic stem cells for the treatment of multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for treatment of multiple sclerosis
Bone marrow-derived stromal cells for multiple sclerosis
Epiblast stem cell-derived oligodendrocyte progenitor cells for multiple sclerosis
FCRx, bioengineered hematopoietic stem cells for immunological tolerance
Hematopoietic stem cells for multiple sclerosis
MultiStem�, bone marrow-derived cells for neurological disorders
NU211-01/NU215-02, umbilical cord mesenchymal stem cells for multiple sclerosis and neuromyelitis optica
NurOwn�, mesenchymal stem cells secreting NTF for neurodegenerative diseases
Peripheral blood-derived hematopoietic stem cells for treatment of multiple sclerosis
Placental-derived mesenchymal stem cells for treatment of multiple sclerosis
Stem cell-derived oligodendrocyte precursor cells for multiple sclerosis
Tcelna�, autologous T-cell immunotherapy for multiple sclerosis
Umbilical cord tissue-derived mesenchymal stem cells for teatment of multiple sclerosis
Embryonic/Adult Cultured Cells Related to Multiple Sclerosis:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19378207
Bone marrow-derived mesenchymal stem cells PMIDs: 22277374
Bone marrow-derived mesenchymal stem cells PMIDs: 21366911 22236384 22277374
Bone marrow-derived mesenchymal stem cells (family)
Oligodendrocyte progenitor cells PMIDs: 21946668
Facilitating cells PMIDs: 17150368
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Umbilical cord-derived mesenchymal stem cells PMIDs: 20682053
Astrocyte-like cells PMIDs: 19127447 19603590
Peripheral blood-derived hematopoietic stem cells (family)
Placenta-derived mesenchymal stem cells PMIDs: 22638856
Oligodendrocyte precursor cells PMIDs: 19363151
Myelin-reactive T-cells PMIDs: 18465664 21563876 19230777
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: multiple sclerosis

Genetic Tests for Multiple Sclerosis

Genetic tests related to Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Multiple Sclerosis Modifier of Disease Progression 29

Anatomical Context for Multiple Sclerosis

MalaCards organs/tissues related to Multiple Sclerosis:

41
Brain, T Cells, Spinal Cord, Testes, Bone, B Cells, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Sclerosis:
# Tissue Anatomical CompartmentCell Relevance
1 Neural Tube Cortical Sub Ventricular Zone Adult Oligodendrocyte Precursor Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
3 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
4 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
5 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
6 Spinal Cord Spinal Cord White Matter Myelinating Oligodendrocyte Cells Affected by disease
7 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
8 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
16 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
17 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate

Publications for Multiple Sclerosis

Articles related to Multiple Sclerosis:

(show top 50) (show all 9926)
# Title Authors Year
1
Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients. ( 30472587 )
2019
2
Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. ( 30103277 )
2019
3
In vitro antiplasmodial activity and identification, using tandem LC-MS, of alkaloids from Aspidosperma excelsum, a plant used to treat malaria in Amazonia. ( 30201230 )
2019
4
Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis. ( 30531078 )
2019
5
Detecting white matter alterations in multiple sclerosis using advanced diffusion magnetic resonance imaging. ( 30531085 )
2019
6
The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. ( 30539801 )
2019
7
Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis. ( 30408481 )
2019
8
Characterization of residue-specific glutathionylation of CSF proteins in multiple sclerosis - A MS-based approach. ( 30367882 )
2019
9
Gait tests in multiple sclerosis: Reliability and cut-off values. ( 30269001 )
2019
10
Multiple sclerosis - a review. ( 30300457 )
2019
11
Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. ( 30300751 )
2019
12
Impact of sex hormones on immune function and multiple sclerosis development. ( 30222193 )
2019
13
Correlating new directional measures of myelin and axonal integrity in T2-weighted MRI with quantitative histology in multiple sclerosis. ( 30240805 )
2019
14
Validation of a precision tremor measurement system for multiple sclerosis. ( 30243994 )
2019
15
Benefit of sugammadex in a morbidly obese patient with multiple sclerosis and severe respiratory dysfunction. ( 30245284 )
2019
16
Improvement of medical judgments by numerical training in patients with multiple sclerosis. ( 30117230 )
2019
17
Heat Shock Protein 70 and The Risk of Multiple Sclerosis in The Iranian Population. ( 30124009 )
2019
18
Self-reported cognitive function in a large international cohort of people with multiple sclerosis: associations with lifestyle and other factors. ( 30133057 )
2019
19
Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process. ( 30133059 )
2019
20
No evidence of disease activity in people with multiple sclerosis. ( 30102815 )
2019
21
Retinal vascular density in multiple sclerosis: a 1-year follow-up. ( 30102834 )
2019
22
A Foodomics Approach: CE-MS for Comparative Metabolomics of Colon Cancer Cells Treated with Dietary Polyphenols. ( 30426427 )
2019
23
A comprehensive appraisal on Crocus chrysanthus (Herb.) Herb. flower extracts with HPLC-MS/MS profiles, antioxidant and enzyme inhibitory properties. ( 30466026 )
2019
24
LA-ICP-MS/MS improves limits of detection in elemental bioimaging of gadolinium deposition originating from MRI contrast agents in skin and brain tissues. ( 30466933 )
2019
25
Visualization of soluble carbohydrate distribution in apple fruit flesh utilizing MALDI-TOF MS imaging. ( 30471723 )
2019
26
Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue. ( 30472582 )
2019
27
Reactive intermediates and bioactivation pathways characterization of avitinib by LC-MS/MS: In vitro metabolic investigation. ( 30472584 )
2019
28
In vivo phenotyping of cytochrome 450 isoforms involved in the metabolism of anti-HIV and anti-tubercular drugs in human using cocktail approach: An LC-MS/MS analysis. ( 30472588 )
2019
29
An integrative urinary metabolomic study of the therapeutic effect of Guizhi Fuling capsule on primary dysmenorrheal rats based 1H NMR and UPLC-MS. ( 30476863 )
2019
30
Comprehensive MS/MS profiling by UHPLC-ESI-QTOF-MS/MS using SWATH data-independent acquisition for the study of platelet lipidomes in coronary artery disease. ( 30482286 )
2019
31
LC-MS/QTOF identification of phytochemicals and the effects of solvents on phenolic constituents and antioxidant activity of baobab (Adansonia digitata) fruit pulp. ( 30502146 )
2019
32
Simultaneous LC-MS quantification of anthocyanins and non-anthocyanin phenolics from blueberries with widely divergent profiles and biological activities. ( 30502155 )
2019
33
Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods. ( 30503802 )
2019
34
Fatty Acid Metabolome Extraction from Mycobacterial Cells for GC-MS Metabolomics Analysis. ( 30421225 )
2019
35
Total Metabolome Extraction from Mycobacterial Cells for GC-MS Metabolomics Analysis. ( 30421226 )
2019
36
Quantitative Profiling of Endogenous Metabolites Using Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry (HILIC-MS/MS). ( 30421230 )
2019
37
Determining the Mode of Action of Antimalarial Drugs Using Time-Resolved LC-MS-Based Metabolite Profiling. ( 30421232 )
2019
38
GC-MS characterisation of novel artichoke (Cynara scolymus) pectic-oligosaccharides mixtures by the application of machine learning algorithms and competitive fragmentation modelling. ( 30446135 )
2019
39
Polymeric ionic liquid open tubular capillary column for on-line in-tube SPME coupled with UHPLC-MS/MS to determine endocannabinoids in plasma samples. ( 30454565 )
2019
40
Determination of primary fatty acid amides in different biological fluids by LC-MS/MS in MRM mode with synthetic deuterated standards: Influence of biofluid matrix on sample preparation. ( 30368294 )
2019
41
Development and validation of a LC-MS/MS method for the analysis of bisphenol a in polyethylene terephthalate. ( 30372934 )
2019
42
Fast on-fiber derivatization and GC/MS analysis of phytohormones in wheat based on pencil-type coated carbon fibers. ( 30372935 )
2019
43
Dissipation behavior, residue distribution and dietary risk assessment of field-incurred boscalid and pyraclostrobin in grape and grape field soil via MWCNTs-based QuEChERS using an RRLC-QqQ-MS/MS technique. ( 30372941 )
2019
44
Analysis of multiple pesticide residues in polyphenol-rich agricultural products by UPLC-MS/MS using a modified QuEChERS extraction and dilution method. ( 30372964 )
2019
45
Development and comparison of single-step solid phase extraction and QuEChERS clean-up for the analysis of 7 mycotoxins in fruits and vegetables during storage by UHPLC-MS/MS. ( 30372967 )
2019
46
Discrimination of dried sea cucumber (Apostichopus japonicus) products from different geographical origins by sequential windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS)-based proteomic analysis and chemometrics. ( 30372983 )
2019
47
Quantification of potentially toxic elements in food material by laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) via pressed pellets. ( 30373001 )
2019
48
Peptidomic profiling of human milk with LC-MS/MS reveals pH-specific proteolysis of milk proteins. ( 30373006 )
2019
49
Phenolic profile of oils obtained from "horchata" by-products assisted by supercritical-CO2 and its relationship with antioxidant and lipid oxidation parameters: Triple TOF-LC-MS-MS characterization. ( 30373021 )
2019
50
Response to different dietary carbohydrate and protein levels of pearl oysters (Pinctada fucata martensii) as revealed by GC-TOF/MS-based metabolomics. ( 30373048 )
2019

Variations for Multiple Sclerosis

ClinVar genetic disease variations for Multiple Sclerosis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
2 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh38 Chromosome 3, 46373456: 46373487
3 PDCD1 NM_005018.2(PDCD1): c.627+189G> C single nucleotide variant risk factor rs11568821 GRCh37 Chromosome 2, 242793912: 242793912
4 PDCD1 NM_005018.2(PDCD1): c.627+189G> C single nucleotide variant risk factor rs11568821 GRCh38 Chromosome 2, 241851760: 241851760
5 NR1H3 NM_005693.3(NR1H3): c.1244G> A (p.Arg415Gln) single nucleotide variant Pathogenic rs61731956 GRCh38 Chromosome 11, 47268596: 47268596
6 NR1H3 NM_005693.3(NR1H3): c.1244G> A (p.Arg415Gln) single nucleotide variant Pathogenic rs61731956 GRCh37 Chromosome 11, 47290147: 47290147

Copy number variations for Multiple Sclerosis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19629 1 150852910 150853198 Copy number LCE3B Multiple sclerosis
2 82393 14 105506863 105509403 Copy number ADAM6 Multiple sclerosis
3 150742 20 13924145 15981841 Copy number MACROD2 Multiple sclerosis
4 224845 7 38265768 38282444 Copy number TARP Multiple sclerosis

Expression for Multiple Sclerosis

Search GEO for disease gene expression data for Multiple Sclerosis.

Pathways for Multiple Sclerosis

Pathways related to Multiple Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR17 MIR20A MIR223 MIR326
2 11.66 HLA-DQB1 HLA-DRB1 PDCD1
3
Show member pathways
11.47 HLA-DQB1 HLA-DRB1 PDCD1
4
Show member pathways
11.2 CCR5 HLA-DQB1 HLA-DRB1 TNFRSF1A
5 11.06 MIR17 MIR18B MIR20A

GO Terms for Multiple Sclerosis

Cellular components related to Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 MIR17 MIR20A MIR223 MIR326 MIR422A MIR584
2 MHC class II protein complex GO:0042613 8.96 HLA-DQB1 HLA-DRB1

Biological processes related to Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.63 MIR20A NR1H3 TNFRSF1A
2 cellular response to lipopolysaccharide GO:0071222 9.62 CCR5 MIR17 MIR20A NR1H3
3 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.43 HLA-DQB1 HLA-DRB1
4 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.4 MIR17 MIR20A
5 positive regulation of metalloendopeptidase activity GO:1904685 9.37 MBP MIR17
6 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.26 HLA-DQB1 HLA-DRB1
7 gene silencing by miRNA GO:0035195 9.17 MIR17 MIR18B MIR20A MIR223 MIR326 MIR422A
8 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DQB1 HLA-DRB1
9 positive regulation of pulmonary blood vessel remodeling GO:1905111 8.96 MIR17 MIR20A

Molecular functions related to Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR17 MIR18B MIR20A MIR223

Sources for Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
2